Sartorius

Sartorius is a prominent provider of laboratory and process technologies, specializing in equipment and consumables for the biopharmaceutical sector. The company operates through two main divisions: Bioprocess and Lab Products and Services. The Bioprocess division focuses on solutions for the manufacturing of biologic drugs, emphasizing single-use technology, while the Lab Products division offers various laboratory equipment, including scales and filtration systems. Sartorius serves a diverse clientele, including firms in the biotech, pharmaceutical, and food industries, as well as public research institutes. With production facilities in Europe, Asia, and America, Sartorius maintains a significant global presence, supported by sales offices and representatives in over 110 countries. The company is committed to advancing scientific research and innovation, aligning closely with its customers and technology partners to enhance efficiency and quality in critical processes.

Florian Funck

CFO

Maurice Phelan

President, North America

19 past transactions

ViroCell Biologics

Convertible Note in 2024
Virocell Biologics is a contract development and manufacturing organization that specializes in the production of viral vectors and gene-modified cells. The company focuses on facilitating the development of novel cell and gene therapies, allowing these innovations to progress into clinical trials. Virocell Biologics offers a platform designed to ensure a rapid, safe, and reliable transition from laboratory research to clinical application, thereby reducing risks and enhancing the value of emerging therapies. Through its services, Virocell Biologics supports medical researchers by providing the necessary gene-modified cells for their clinical studies.

TheWell Bioscience

Corporate Round in 2024
TheWell Bioscience is a biotechnology company that specializes in 3D cell culture technology aimed at enhancing life science research. The company has developed an innovative cell culture hydrogel system designed to facilitate drug screening, tissue engineering, and pre-clinical studies. By bridging the gap between traditional in vitro studies and in vivo models, TheWell Bioscience provides researchers with a robust platform for drug discovery and personalized medicine. This technology supports scientists in their efforts to conduct more accurate and relevant analyses, ultimately advancing the healthcare industry.

SPARTA Biodiscovery

Seed Round in 2023
Sparta Biodiscovery specializes in providing analytical testing services for nanoparticles used in pharmaceutical and biotechnology industries. The company facilitates nanoformulations for upcoming therapies, offering simultaneous size and chemical compositional analysis on a single-particle basis, catering to diagnostic and therapeutic purposes.

Polyplus-transfection

Acquisition in 2023
Polyplus-transfection SA is a biotechnology company based in Illkirch-Graffenstaden, France, specializing in the development and sale of solutions for nucleic acid delivery across research, bioproduction, and therapeutic applications. Established in 2001 and ISO 9001-certified since 2002, the company offers a diverse range of proprietary reagents for the transfection of genes, oligonucleotides, and siRNA. These products facilitate various applications including enhanced in vivo delivery, molecular biology, diagnostics, gene expression, RNA interference, and protein production. Polyplus-transfection's reagents are increasingly utilized in clinical trials globally, supported by a network of distributors. The company also holds a comprehensive portfolio of patents and licenses, featuring innovative methods for therapeutic siRNA delivery.

Albumedix

Acquisition in 2022
Albumedix is a biotechnology company based in Nottingham, England, that specializes in developing albumin-based drug enhancement technologies to create superior biopharmaceuticals. With a focus on improving therapies for serious diseases, the company partners with pharmaceutical organizations to deliver advanced drug and vaccine formulations. Its product offerings include drug stabilization, cell therapy formulation, and drug conjugates, which help clients in formulating effective treatments. With a dedicated team of over 80 professionals, Albumedix is recognized as a leader in the industry, contributing to both clinical and marketed drugs while remaining committed to enhancing patient quality of life through innovative albumin-enabled therapies.

Novasep - Chromatography Equipment

Acquisition in 2022
Novasep - Chromatography Equipment comprises resin-based batch and intensified chromatography systems, and focuses on low & high pressure for small and large molecules such as monoclonal antibodies, oligonucleotides, peptides and insulin.

ALS Automated Lab Solutions

Acquisition in 2021
ALS Automated Lab Solutions specializes in providing advanced laboratory services tailored for life science applications. Its flagship product, the ALS CellCelector, is an automated system designed for mammalian cell line generation. This innovative platform enables the scanning of cell culture plates to identify and select target cells or colonies with high precision. By integrating advanced robotic technology with sophisticated image processing software, the CellCelector offers exceptional image quality and real-time quality control during the picking process. The use of disposable tips eliminates the risk of cross-contamination, while the system's design ensures minimal maintenance requirements. Overall, ALS Automated Lab Solutions aims to enhance efficiency and accuracy in laboratory workflows, ultimately benefiting scientists in their research endeavors.

Xell

Acquisition in 2021
Xell is a partner for biotech and pharmaceutical companies, specializing in cell culture technology to enhance the production of biopharmaceuticals, diagnostic proteins, viral vectors, and vaccines. The company offers a diverse product portfolio that includes cell culture media, feeds, dietary supplements, and customized formulations tailored to meet the specific needs of its clients. With a team of experienced experts, Xell focuses on delivering efficient solutions for cell culture challenges, leveraging advanced analytical tools for the characterization of biological systems and pharmaceutical proteins. By collaborating closely with customers, Xell aims to optimize their bioprocesses and improve overall production capabilities in the healthcare sector.

CellGenix

Acquisition in 2021
CellGenix is a manufacturer specializing in raw and ancillary materials for cell and gene therapy as well as regenerative medicine. The company develops, produces, and markets human cytokines, growth factors, and other recombinant cell culture components, offered in both preclinical and GMP quality. Additionally, CellGenix provides proprietary serum-free media specifically designed for the manufacturing of Advanced Therapy Medicinal Products (ATMPs). Their products support academia and industry partners in clinical trials and commercial manufacturing globally. With extensive expertise in cell culture and regulatory processes, CellGenix is well-equipped to meet the stringent requirements faced by customers during product development and regulatory approval.

Biological Industries

Acquisition in 2019
Biological Industries is a manufacturer focused on developing life science research products, particularly in the areas of cell culture and molecular biology. The company specializes in creating cell culture media tailored for stem cell research and potential cell therapy applications. Its offerings include products for stem cell culture and differentiation, human cytogenetics, tissue culture, and custom cell media formulation. Additionally, Biological Industries provides services in contract manufacturing, mycoplasma detection and elimination, as well as cell proliferation and viability assessments. Furthermore, the company produces QF-PCR test kits, supporting academic institutions, biotechnology firms, and pharmaceutical companies with innovative solutions in the fields of cell therapy and molecular biology.

Danaher Life Science

Acquisition in 2019
Danaher Life Sciences provide scientists with meaningful research tools and services to gain a better understanding of biological and chemical matters. The combined efforts of Beckman Coulter Life Sciences, SCIEX, Molecular Devices, Pall, and Leica Microsystems work synergistically to provide increasingly sophisticated technologies designed to integrate across systems faster and with more accurate data.

ForteBio

Acquisition in 2019
ForteBio is a life science company focused on developing analytical systems for protein quantification and the characterization of protein-protein interactions. The company offers the Octet family of instruments, which facilitate real-time analysis of biomolecular interactions using micro-volume samples. These instruments provide essential data on affinity, kinetics, and concentration for proteins, peptides, DNA, RNA, and small molecules. Key products in the Octet line include the Octet RED, which is designed for quantitation and kinetics analysis while also enhancing the range and resolution for small molecule screening, as well as the Octet Q and QK models that perform similar analytical functions. By enabling rapid, real-time results, ForteBio's systems support scientists in their research endeavors.

MKS Umetrics

Acquisition in 2017
MKS Umetrics is a prominent provider of data analytics software focused on enhancing biopharmaceutical development and manufacturing processes. The company's software solutions include tools for predictive modeling, design of experiments (DOE), and multivariate data analysis (MVDA). These offerings enable clients to optimize their operations and improve decision-making by leveraging advanced analytical methodologies. Through its innovative software, MKS Umetrics aims to add significant value to businesses in the biopharmaceutical sector.

Essen BioScience

Acquisition in 2017
Essen BioScience Inc. specializes in developing and manufacturing instruments, software, reagents, and consumables for life science research globally. The company's flagship product is the IncuCyte S3, a real-time quantitative live-cell imaging and analysis platform that allows researchers to visualize and quantify cell behavior continuously over extended periods, utilizing standard laboratory incubators. This technology facilitates the automatic gathering and analysis of images, enabling scientists to conduct live-cell experiments and derive quantitative data. Established in 1996 and based in Ann Arbor, Michigan, Essen BioScience has had a significant impact on the field of cell-based in vitro assays, with innovations recognized as "first in class" in various technology areas. The company operates as a subsidiary of Sartorius Aktiengesellschaft and has sales entities in the United Kingdom and Japan.

ViroCyt

Acquisition in 2016
ViroCyt is a company based in Broomfield, Colorado, founded in 2012, that specializes in the rapid quantification of viruses through innovative technologies. The company aims to enhance critical processes in various fields, including vaccine manufacturing, protein expression, and antiviral development. Its tools are designed to support vaccine companies, biotechnology firms, and research institutions, both domestic and international, where the accurate measurement of viruses is essential. By focusing on the commercialization of its technologies, ViroCyt seeks to improve efficiency and effectiveness in areas significantly impacted by viral activity.

kSep Systems

Acquisition in 2016
kSep Systems, LLC specializes in automated single-use bioprocessing solutions tailored for the biopharmaceutical industry, particularly in recombinant therapeutics, cell therapy, and vaccine manufacturing. The company's flagship technology, kSep, enables efficient harvesting of cells as either a product or by-product during the manufacturing process. This innovative system retains particles, such as cells or microcarriers, in a concentrated fluidized bed while maintaining a continuous flow of media or buffer. kSep Systems addresses the limitations of traditional centrifugation methods by providing fully automated, gentle processing environments that enhance the concentration, washing, and separation of cells, thereby ensuring high recovery rates. Founded in 2011 and headquartered in Morrisville, North Carolina, kSep Systems operates as a subsidiary of Sartorius Stedim Biotech S.A., building on its legacy as a former subsidiary of KBI Biopharma Inc.

IntelliCyt

Acquisition in 2016
IntelliCyt Corporation specializes in the development of high-throughput cell- and bead-based screening solutions tailored for the life sciences sector, particularly in drug discovery, antibody development, and immunology. Founded in 2006 and based in Albuquerque, New Mexico, the company offers a comprehensive iQue Screener platform that integrates instrumentation, software, and reagents to facilitate high-content multiplex analysis of samples in liquid suspension. This platform is complemented by ForeCyt software for data visualization and analysis, as well as MultiCyt screening kits designed for use with iQue Screeners. IntelliCyt’s innovative technologies significantly enhance the efficiency and cost-effectiveness of detecting and measuring cells and beads, addressing critical needs in pharmaceutical and biotechnology laboratories globally. As a subsidiary of Sartorius AG, IntelliCyt continues to lead in providing solutions that meet the demands of modern life sciences research while ensuring rapid and relevant results in various applications, including phenotypic small molecule drug discovery and in vitro toxicology.

Cellca

Acquisition in 2015
Cellca is a specialized technology and service provider that focuses on upstream technologies for mammalian protein manufacturing. The company develops cell lines and offers fermentation processes for biopharmaceutical products, emphasizing process development for large-scale production of biologics in mammalian cells. Cellca's proprietary technologies are designed to enhance the efficiency, robustness, and scalability of mammalian protein manufacturing, making it faster and more cost-effective.

TAP Biosystems Group

Acquisition in 2013
TAP Biosystems focuses on the design and manufacture of automated cell culture and fermentation systems. The company develops and supplies technology that is utilized in pharmaceutical, biotechnology, and academic laboratories. Their systems support bioprocess development and good manufacturing practice (GMP) production of biologics and cell therapies, as well as facilitate discovery and stem cell research programs. TAP Biosystems plays a vital role in advancing research and production capabilities within the life sciences sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.